Search clinical trials for: X4P-001

Total 4474 results

X4 Pharmaceuticals

Completed

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Neutropenia

United States
X4 Pharmaceuticals

Completed

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome

United States, Australia
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
X4 Pharmaceuticals

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Neutropenia

United States, Spain, France, Thailand, United Kingdom, Germany, Romania, Hungary, India, Serbia, Czechia, Georgia, Australia, Argentina, Greece, Italy, Portugal, Turkey, Ukraine, Canada, Israel, Switzerland
Abbisko Therapeutics Co, Ltd

Enrolling by invitation

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Triple Negative Breast Cancer

China
X4 Pharmaceuticals

Active, not recruiting

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome

United States, Denmark, Australia, Austria, France, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Russian Federation, Spain, Turkey
University of Pennsylvania

Terminated

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
Revibe Technologies

Completed

Assessing a Wearable Digital Therapy for Youth With ADHD

ADHD

United States
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
Patagonia Pharmaceuticals, LLC

Completed

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Congenital Ichthyosis

United States
X4 Pharmaceuticals

Completed

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma (X4P-001-MELA)

Melanoma

United States
Synthekine

Recruiting

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects with Severe, Refractory Systemic Autoimmune Rheumatic Disease

Systemic Lupus Erythematosus | Systemic Sclerosis | Lupus Nephritis

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Subjects With Asthma

Asthma
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
EGEN, Inc.

Terminated

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Ovarian Neoplasms

United States
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
X4 Pharmaceuticals

Terminated

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
X4 Pharmaceuticals

Completed

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States, Korea, Republic of
AeroRx Therapeutics Inc.

Recruiting

Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD

COPD

United Kingdom
X4 Pharmaceuticals

Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Waldenstrom's Macroglobulinemia

United States, Greece
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
Pfizer

Completed

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Smoking | Vaccines

Canada
National Cancer Institute (NCI)

Completed

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Head and Neck Cancer | Head and Neck Neoplasms

United States
EGEN, Inc.

Completed

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Ovarian Neoplasms

United States
Dr. August Wolff GmbH & Co. KG Arzneimittel
Parexel

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients

Dermatitis, Atopic

Germany
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
101 Therapeutics

Active, not recruiting

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Virus Diseases | COVID-19 | Infectious Disease | Glucocorticoids Toxicity

India
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Antengene Corporation

Terminated

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (MATCH)

Relapsed/Refractory Diffuse Large B-cell Lymphoma

China
Pacylex Pharmaceuticals
Ozmosis Research Inc.

Completed

Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma

Advanced Solid Tumor | B-cell Non Hodgkin Lymphoma

Canada
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

Limbal Stem Cell Deficiency

United States
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

COVID-19 Vaccine

Australia
IVIEW Therapeutics Inc.

Completed

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Corneal Scar

United States
Cryonove Pharma
CEISO; Dermatech; Sefako Makgatho Health Sciences University

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.

Solar Lentigo | Post-inflammatory Hyperpigmentation | Senile Lentigo

South Africa
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar

Georgia
Claris Biotherapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Neurotrophic Keratitis

United States, Canada
IntegoGen, LLC

Withdrawn

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
S-Alpha Therapeutics, Inc.

Completed

Exploratory Study on the Effect of SAT-001 on Choroidal Thickness in Pediatric Myopia Patients

Myopia

Korea, Republic of
University of Aarhus
Odense University Hospital; Oslo University Hospital; Rigshospitalet, Denmark; Hvidovre... and other collaborators

Completed

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN)

HIV-1-infection

Norway, Denmark, United States, Australia
JANSSEN Alzheimer Immunotherapy Research & Development...

Terminated

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Toll Biotech Co. Ltd. (Beijing)

Recruiting

A Study of Single and Multiple Oral Doses of TollB-001

Rheumatoid Arthritis

China
Heartseed Inc.

Active, not recruiting

A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) (LAPiS)

Heart Failure | Ischemic Heart Disease

Japan
Okyo Pharma Ltd
Tufts Medical Center

Recruiting

The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain

Neuropathic Pain

United States
Eikon Therapeutics
Impact Therapeutics, Inc.

Not yet recruiting

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. (EIK1004-001)

Advanced Solid Tumors

Search clinical trials for: X4P-001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations